Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Hair regrowth was sustained through week 48 in patients with response at week 24. Up to one-third of patients who did not meet target efficacy at week 24 achieved response with continued ritlecitinib treatment.
Authors
- Lindsey A. Bordone
- Charles W Lynde (ORCID: https://orcid.org/0000-0001-9163-5463)
- Dalia Wajsbrot
- Samuel H. Zwillich (ORCID: https://orcid.org/0009-0003-9103-4176)
- Melissa Piliang
- Rodney Sinclair (ORCID: https://orcid.org/0000-0001-6751-1428)
- Maryanne M. Senna (ORCID: https://orcid.org/0000-0002-7813-520X)
- Haytham Mohamed Ahmed (ORCID: https://orcid.org/0000-0002-2883-3317)
- Paradi Mirmirani (ORCID: https://orcid.org/0000-0001-8627-2995)
- Brett King (ORCID: https://orcid.org/0000-0002-4576-4616)
- P. de la Cueva Dobao
- Seth Forman (ORCID: https://orcid.org/0000-0001-5800-1856)
- Liza Takiya (ORCID: https://orcid.org/0000-0002-6296-7685)
- Robert A. Wolk (ORCID: https://orcid.org/0000-0001-8581-6647)
- Helen Tran (ORCID: https://orcid.org/0009-0007-6053-6703)
Institutions
- Cleveland Clinic (US)
- Pfizer (United States) (US)
- University of Toronto (CA)
- Columbia University Irving Medical Center (US)
- Yale University (US)
- Lahey Medical Center (US)
- Kaiser Permanente Vallejo Medical Center (US)
- MemorialCare Health System (US)
- Sinclair Dermatology (AU)
- Hospital Universitario Infanta Leonor (ES)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1016/j.jaad.2024.09.064
- Citations
- 7
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- Pfizer